News and Announcements
Kazia Therapeutics (ASX: KZA) raised $6M in 2019 detailed in recently released Annual Report
- Published August 29, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Kazia has released its FY19 Annual Report. Notable highlights are listed below.
- GDC-0084 has completed a Phase I clinical trial with Genentech and is now undergoing a Phase II clinical trial in glioblastoma, sponsored by Kazia, focusing on newly diagnosed patients.
- Cantrixil is currently in a Phase I clinical trial which has established a MTD of 5 mg/kg and has shown pleasing efficacy signals in the first phase of this trial.
- $6,174,832 funds generated from capital raise and sale of shares during FY19, substantially funding our operations for the year
To read the full report, click here.
About Kazia Therapeutics (ASX: KZA)
Kazia Therapeutics is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. Headquartered
in Sydney, Australia, Kazia Therapeutics collaborates with leading scientists, clinicians, and investors around the world.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
